Epstein-Barr virus (EBV) infects and establishes latency in B lymphocytes (for reviews, see references 12, 15, and 27). The virus has been implicated in the etiology of malignancies such as Burkitt's lymphoma (BL) (6, 11, 18, 28) and in lymphoproliferative diseases in the immunocompromised host, including posttransplant lymphoproliferative disorders (PTLDs) and AIDS-related lymphomas (1, 2, 8, 10, 16, 25, 28) . The high rate of mortality associated with the development of PTLDs has prompted several groups to retrospectively analyze EBV load in peripheral blood, virus shedding, localization of in situ markers for virus (by using an EB-encoded RNA [EBER] probe), and the anti-EBNA specific antibody responses in efforts to identify prognostic markers of disease (14, 19, 20, 31) . Many of these assays either are not specifically correlated with the pathogenesis process (e.g., viral shedding and antibody response) or are invasive (i.e., require biopsy specimen) and are subject to possible sampling error.
The use of PCR for EBV DNA has been suggested as a rapid indicator of immunopathological changes preceding and/or underlying the development of a lymphoproliferative disorder. Several studies using a limited number of patients and semiquantitative PCR procedures indicated that high levels of EBV DNA were associated with development of PTLDs (9, 19, (22) (23) (24) . This paper details the development of a quantitative competitive PCR (QC-PCR) assay which is both sensitive and accurate and describes the use of this assay to determine EBV genome loads at the time of PTLD diagnosis. In the QC-PCR reaction mixture, a competitor target molecule of known concentration competes with the virus-derived target sequence for primers, polymerase, and substrates. If after PCR amplification the amount of the amplified virus DNA product and the amount of competitor DNA product are equal, then it is assumed that the initial starting concentrations of the two targets were also equal.
QC-PCR for EBV DNA was performed on specimens from both healthy seropositive adult volunteers and children who had undergone solid-organ transplantation at the Children's Hospital of Pittsburgh. Specimens were obtained from the pediatric transplant recipients both in the absence and in the presence of clinical or histological evidence of EBV infection or a PTLD. PTLDs were diagnosed by using both clinical and histological criteria. Children were considered to have clinical evidence suggestive of a PTLD when there was evidence of lymphadenopathy, tonsillar hypertrophy (with or without an exudate), or extranodal masses on physical examination; when nodular or ulcerative lesions were evident during gastrointestinal endoscopy; and/or when there was radiological evidence suggestive of lymphadenopathy or extranodal masses. A novel scoring system has been designed for histological grading of EBV infection within intestinal tissue. Tissue specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin for histological examination. The presence of EBV infection was determined by EBER staining and scored according to the number of EBER-positive cells present. A PTLD diagnosis required a score of either 3 or 4 in the histopathology analysis or a score of 2 and clinical evidence of a PTLD. For extraintestinal tissue, mononucleosis and PTLD were defined according to previously published guidelines (17, 26) .
For a QC-PCR test, approximately 2 ml of blood was drawn and lymphocytes were separated from whole blood by centrifugation onto a Histopaque (Sigma) cushion. The cells were washed with phosphate-buffered saline and counted. A sample of plasma and at least two tubes of cells, each containing 1 ϫ 10 6 to 5 ϫ 10 6 peripheral blood lymphocytes (PBLs), were frozen at Ϫ30°C. To make the lymphocyte lysate, one tube of PBLs was thawed in 20 l of PCR lysis buffer (50 mM KCl, 10 mM Tris [pH 7.6], 2.5 mM MgCl 2 , 1% Tween 20, and 100 g of proteinase K per ml) per 10 5 PBLs. The lysate was incubated at 50°C for 1 h, boiled for 10 min to inactivate the protease, and chilled on ice before being used for PCR. To measure the EBV genome load in small volumes of blood rapidly and accurately, a QC strategy was selected because it allows relative amounts of patient-derived viral DNA to be coamplified under exactly the same conditions as a known quantity of a slightly shorter related DNA target sequence, thus permitting sample, primer pair, and target sequence variation to be internally controlled. The copy number of the competitor plasmid was measured, with Namalwa cell DNA being used as the control. Namalwa is a BL cell line which contains two integrated copies of the viral genome per cellular genome. Counting Namalwa cells is therefore equivalent to counting the viral (and cellular) DNA copy number. Since we planned to use a crude lysate of 10 5 PBLs in 50-l PCR volumes for our assay, EBV-negative BJAB cells were mixed with known numbers of Namalwa cells to simulate the presence of small numbers of infected cells in a background of large numbers of uninfected cells. A series of competitive PCRs was then performed with the plasmid competitor, and the concentration of the competitor was adjusted so that band intensities would be equivalent after amplification. PCRs were performed with cycling controls (varying the number of cycles of amplification) and dilution controls (varying the concentrations of Namalwa cells and the plasmid competitor), and mock quantitations were done. From these studies, conditions were established under which quantitation was accurate and reproducible.
For each assay, five tubes, containing 5,000, 1,000, 200, 40, or 8 copies of the viral latent membrane protein 2a (LMP2a) competitor and lysate with 10 5 PBLs, were subjected to 30 cycles of amplification (94°C for 1 min, 54°C for 1 min, and 72°C for 1 min). The 5Ј and 3Ј primers were adjusted to 20 pmol per 50 l of a reaction mixture containing 50 mM KCl, 2.5 mM MgCl 2 , 10 mM Tris-HCl (pH 9.0 at 25°C), 0.1% Triton X-100, and 0.25 mM deoxynucleotides (Pharmacia). One unit of Taq DNA polymerase (Promega) was used in each reaction. PCR products were analyzed on 2% agarose gels containing 0.5ϫ Tris-borate-EDTA electrophoresis buffer and 0.5 g of ethidium bromide per ml. Figure 1 shows the quantitation of the EBV genome load in PBLs by QC-PCR amplification. For this patient's PBL specimen, the viral load was determined to be approximately 400 copies per 10 5 cells (Fig. 1A) . The number of cells present in the PCR lysate was predetermined by cell counting; however, this number was confirmed by QC-PCR amplification of an HLA-DQ␣ gene sequence in the presence of a competitor at 5 ϫ 10 5 , 10 5 , and 2 ϫ 10 4 copies (Fig. 1B) . This capability allows the determination of the EBV genome load on a percell basis even in samples for which the cell number is not known and provides an independent control for the integrity and amplifiability of DNA in the cell lysate. Although EBV copy numbers between 200 and 5,000 are easily detected on ethidium bromide-stained gels, sensitivity over the entire range (8 to 5,000) has required Southern blotting and hybridization with oligonucleotide probes. The results of a Southern analysis for another patient with a viral genome burden determined to be 80 copies per 10 5 PBLs is also shown (Fig. 1C and D) . The estimation of the viral DNA concentration has been made by interpolation of phosphorimage quantitation of bands on a Southern blot probed with 32 PO 4 -labeled oligonucleotides complementary to the EBV target sequence (Molecular Dynamics). The reproducibility of the test was examined by repeat testing of this sample. The average value for seven tests was 71.4. The highest value obtained was 120 and the lowest was 40. All values were therefore within a factor of 2 of the initially determined value.
A total of 122 assays have been performed on 26 pediatric transplant patients. Viral DNA was detected in 83 of the assays, 35 were negative, and 4 samples failed to amplify. In three of the four amplification failures, erythrocyte lysis was noted in the sample. Failures were easily recognized when the control HLA titration did not work and when the viral LMP2a competitor DNA did not amplify. Fourteen of the 26 children met the histological and clinical criteria for PTLD. Thirteen of the 14 pediatric transplant recipients with PTLDs had viral genome loads equal to or greater than 500 copies per 10 5 PBLs (Table 1) . The patient with a PTLD whose viral load was estimated to be 20 represents a special case. This child had recently undergone a second isolated intestinal transplantation 2 years after removal of his initial graft as part of the treatment of the PTLD. The recurrent PTLD lesion in his new graft was present only transiently, despite the regimen of strong immunosuppression (including multiple courses of OKT3) as a treatment for severe rejection. None of the other children with PTLD diagnoses had a prior history of a PTLD. As reported previously (22) (23) (24) and as quantified by QC-PCR, very high genome burdens associated with PBL (4 to 6 orders of magnitude greater than latency) correlate with a PTLD diagnosis. Performance specifications were calculated for the QC-PCR test assuming a value of Ͼ200 EBV genomes per 10 5 PBLs as a positive test predictive of a PTLD. The sensitivity of the assay for PTLDs was 92.8% (13/14) , while the specificity was 100%. In contrast, performance of QC-PCR on samples from 12 pediatric transplant patients for whom there was no evidence of symptomatic EBV infection or a PTLD showed that all had EBV titers of Յ200 (Table 2) . Gastrointestinal biopsy specimens obtained at or near the time of the QC-PCR measurement were available for 9 of the 12 patients, and EBERpositive cells were not identified in any of these patients.
The copy number of EBV genomes in healthy carriers has previously been estimated to be between 0.01 and 0.1 copies per 10 5 PBL (30). Since our assay measures between 8 and 5,000 copies in 10 5 cells, latent virus infections are not usually detected. To use this assay to estimate the DNA copy number in latently infected PBLs, B cells from healthy seropositive donors were purified. PBLs from 100 ml of blood were harvested, washed once with phosphate-buffered saline, and resuspended in RPMI 1640 without serum. The PBLs were then incubated at 4°C in a 5:1 ratio with anti-CD19-coated magnetic beads (Dynal) for 30 min. The proportion of B cells in the PBL population obtained after Histopaque separation was determined by flow cytometry with fluorescein-tagged anti-CD19. The bead-attached cells were directly lysed in lysis buffer, and the number of cells recovered was determined by QC-PCR with the HLA-DQ␣ target. For 10 donors, the values ranged from not detectable to 40 copies per 10 5 B cells (Table 3) . Estimations of the number of copies per 10 5 PBLs (when detected) ranged from 0.1 to 2 copies per 10 5 lymphocytes. Our understanding of PTLD pathogenesis is limited by our rudimentary knowledge of the mechanisms responsible for establishing and maintaining EBV latency and causing episodic reactivation of latent virus in normal individuals. Studies conducted here and elsewhere have shown the PTLDs represent a disease that evolves, initiating with a polyclonal lymphoproliferation and ending with the emergence of a malignant lymphoma refractory to immune regulation. The evolutionary process almost invariably selects a monoclonal, monomorphic cell population, yet a particular cell type (such as in BL) has not been identified. Specific chromosomal abnormalities are not associated with PTLD lesions or lymphoblastoid cell lines derived from PTLD lesions, with the exception of an infrequent c-myc 8; 14 translocation (found in only 3 of 37 analyses to date). Moreover, the observation that both restricted and lymphoblastoid cell line-like latent viral phenotypes are associated with monoclonal PTLDs suggests that selection for a particular pattern of EBV gene expression is not a prerequisite for development of a malignant PTLD cell (5, 7, 26) . The heterogeneity of PTLDs has led to a multipathway model for PTLD progression to account for the reported differences in EBV gene expression and B-cell phenotypes (4, 5, 8, 21, 28) .
To date there have been only a few studies that have made estimates of EBV genome burden in the PBLs of patients with PTLDs. The preliminary data collected by Riddler et al. (22) provided evidence for an association between high copy num- PBLs. This result is in agreement with previous estimates and provides a valuable baseline for our quantitative measurements in patients' blood samples (3, 29, 30) . The middle of the test range (200 copies per 10 5 PBLs) is 3 orders of magnitude above the latent burden, and therefore estimates become reliable for purely stochastic reasons only when the measured burden is 2 orders of magnitude above latency (i.e., when the number of viral genomes in the reaction tube is greater than 20). Of the 14 pediatric transplant recipients with PTLDs, 13 had EBV genome burdens of greater than 500 copies per 10 5 PBLs (median, 4,000). Because of the 3 to 4 order of magnitude difference in viral genome burden between latency and PTLD in this patient population, there exists an opportunity to use this assay to detect the EBV burden as it increases and possibly before the diagnostic features of PTLDs arise. In summary, the QC-PCR for EBV appears to provide a sensitive and specific tool to augment the diagnosis of PTLDs in pediatric organ transplant recipients. 
